Lloyds Banking Group to Close Invoice Factoring Business by End of 2025 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccine Portfolio 
BlackRock-Backed Global Ports Deal Faces Uncertainty Amid Cosco Demands 
California DMV Proposes New Safety Rules for Autonomous Vehicles After Waymo Incidents 
Hyundai Recalls Over 51,000 Vehicles in the U.S. Due to Fire Risk From Trailer Wiring Issue 
Nvidia to Acquire Groq in $20 Billion Deal to Boost AI Chip Dominance 
Texas App Store Age Verification Law Blocked by Federal Judge in First Amendment Ruling 
L&F Tesla Battery Supply Deal Value Drops Sharply Amid EV Market Slowdown 
China’s LandSpace Takes Aim at SpaceX With Reusable Rocket Ambitions 
Nike Stock Jumps After Apple CEO Tim Cook Buys $2.9M Worth of Shares 
Brazilian Oil Workers’ Strike Continues as Key Petrobras Union Rejects Proposal 
BP’s Castrol Stake Sale Raises Debt Relief Hopes but Sparks Cash Flow Concerns 
Trump Administration Probes Corporate DEI Programs, Raising Questions for Google Stock 
GLP-1 Weight Loss Pills Set to Reshape Food and Fast-Food Industry in 2025 
Winter Storm Devin Triggers Massive Flight Cancellations and Travel Disruptions Across the U.S. 
Nvidia and Groq Strike Strategic AI Inference Licensing Deal 
CRANBURY, N.J., March 02, 2016 -- Amicus Therapeutics (Nasdaq:FOLD), a biotechnology company at the forefront of therapies for rare and orphan diseases, today announced that Bradley L. Campbell, President and Chief Operating Officer, will present a corporate overview at the Cowen and Company 36th Annual Health Care Conference in Boston, MA on Wednesday, March 9, 2016 at 8:40 a.m. ET.
An audio webcast of the presentation can be accessed through the Investors section of the Amicus Therapeutics corporate web site at http://ir.amicustherapeutics.com/events.cfm, and will be archived for 90 days.
About Amicus Therapeutics
Amicus Therapeutics (Nasdaq:FOLD) is a biotechnology company at the forefront of therapies for rare and orphan diseases. The Company has a robust pipeline of advanced therapies for a broad range of human genetic diseases. Amicus’ lead programs in development include the small molecule pharmacological chaperone migalastat as a monotherapy for Fabry disease, SD-101 for Epidermolysis Bullosa (EB), as well as novel enzyme replacement therapy (ERT) products for Fabry disease, Pompe disease, and other Lysosomal Storage Disorders.
FOLD–G
CONTACTS: Investors/Media: Amicus Therapeutics Sara Pellegrino Senior Director, Investor Relations [email protected] (609) 662-5044 Media: Pure Communications Dan Budwick [email protected] (973) 271-6085
